These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

127 related articles for article (PubMed ID: 34959173)

  • 1. Redesigning of the cap conformation and symmetry of the diphenylethyne core to yield highly potent pan-genotypic NS5A inhibitors with high potency and high resistance barrier.
    Abdallah M; Hamed MM; Frakolaki E; Katsamakas S; Vassilaki N; Bartenschlager R; Zoidis G; Hirsch AKH; Abdel-Halim M; Abadi AH
    Eur J Med Chem; 2022 Feb; 229():114034. PubMed ID: 34959173
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Daclatasvir-like inhibitors of NS5A block early biogenesis of hepatitis C virus-induced membranous replication factories, independent of RNA replication.
    Berger C; Romero-Brey I; Radujkovic D; Terreux R; Zayas M; Paul D; Harak C; Hoppe S; Gao M; Penin F; Lohmann V; Bartenschlager R
    Gastroenterology; 2014 Nov; 147(5):1094-105.e25. PubMed ID: 25046163
    [TBL] [Abstract][Full Text] [Related]  

  • 3. HCV NS5A replication complex inhibitors. Part 4. Optimization for genotype 1a replicon inhibitory activity.
    St Laurent DR; Serrano-Wu MH; Belema M; Ding M; Fang H; Gao M; Goodrich JT; Krause RG; Lemm JA; Liu M; Lopez OD; Nguyen VN; Nower PT; O'Boyle DR; Pearce BC; Romine JL; Valera L; Sun JH; Wang YK; Yang F; Yang X; Meanwell NA; Snyder LB
    J Med Chem; 2014 Mar; 57(5):1976-94. PubMed ID: 23573957
    [TBL] [Abstract][Full Text] [Related]  

  • 4. HCV NS5A replication complex inhibitors. Part 5: discovery of potent and pan-genotypic glycinamide cap derivatives.
    Belema M; Nguyen VN; St Laurent DR; Lopez OD; Qiu Y; Good AC; Nower PT; Valera L; O'Boyle DR; Sun JH; Liu M; Fridell RA; Lemm JA; Gao M; Knipe JO; Meanwell NA; Snyder LB
    Bioorg Med Chem Lett; 2013 Aug; 23(15):4428-35. PubMed ID: 23803586
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Orally bioavailable HCV NS5A inhibitors of unsymmetrical structural class.
    Nakamura H; Fujioka S; Terui T; Okuda S; Kondo K; Tamatani Y; Akagi Y; Komoda Y; Kinoshita W; Ito S; Maeda K; Ukaji Y; Inaba T
    Bioorg Med Chem Lett; 2020 Sep; 30(17):127361. PubMed ID: 32738974
    [TBL] [Abstract][Full Text] [Related]  

  • 6.
    Ng TI; Krishnan P; Pilot-Matias T; Kati W; Schnell G; Beyer J; Reisch T; Lu L; Dekhtyar T; Irvin M; Tripathi R; Maring C; Randolph JT; Wagner R; Collins C
    Antimicrob Agents Chemother; 2017 May; 61(5):. PubMed ID: 28193664
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prevalence of polymorphisms with significant resistance to NS5A inhibitors in treatment-naive patients with hepatitis C virus genotypes 1a and 3a in Sweden.
    Lindström I; Kjellin M; Palanisamy N; Bondeson K; Wesslén L; Lannergard A; Lennerstrand J
    Infect Dis (Lond); 2015 Aug; 47(8):555-62. PubMed ID: 25851241
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Resensitizing daclatasvir-resistant hepatitis C variants by allosteric modulation of NS5A.
    Sun JH; O'Boyle DR; Fridell RA; Langley DR; Wang C; Roberts SB; Nower P; Johnson BM; Moulin F; Nophsker MJ; Wang YK; Liu M; Rigat K; Tu Y; Hewawasam P; Kadow J; Meanwell NA; Cockett M; Lemm JA; Kramer M; Belema M; Gao M
    Nature; 2015 Nov; 527(7577):245-8. PubMed ID: 26536115
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Differential sensitivity of 5'UTR-NS5A recombinants of hepatitis C virus genotypes 1-6 to protease and NS5A inhibitors.
    Li YP; Ramirez S; Humes D; Jensen SB; Gottwein JM; Bukh J
    Gastroenterology; 2014 Mar; 146(3):812-821.e4. PubMed ID: 24262279
    [TBL] [Abstract][Full Text] [Related]  

  • 10. In vitro activity and resistance profile of samatasvir, a novel NS5A replication inhibitor of hepatitis C virus.
    Bilello JP; Lallos LB; McCarville JF; La Colla M; Serra I; Chapron C; Gillum JM; Pierra C; Standring DN; Seifer M
    Antimicrob Agents Chemother; 2014 Aug; 58(8):4431-42. PubMed ID: 24867983
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Evaluation of antiviral effects of novel NS5A inhibitors in hepatitis C virus cell culture system with full-genome infectious clones.
    Murayama A; Fujiwara K; Yamada N; Shiina M; Aly HH; Masaki T; Muramatsu M; Wakita T; Kato T
    Antiviral Res; 2018 Oct; 158():161-170. PubMed ID: 30118732
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Exploring small molecules with pan-genotypic inhibitory activities against hepatitis C virus NS3/4A serine protease.
    Ren J; Ojeda I; Patel M; Johnson ME; Lee H
    Bioorg Med Chem Lett; 2019 Aug; 29(16):2349-2353. PubMed ID: 31201062
    [TBL] [Abstract][Full Text] [Related]  

  • 13. In vitro resistance profile of hepatitis C virus NS5A inhibitor velpatasvir in genotypes 1 to 6.
    Dvory-Sobol H; Han B; Lu J; Yu M; Beran RK; Cheng G; Martin R; Svarovskaia E; Mo H
    J Viral Hepat; 2019 Aug; 26(8):991-1001. PubMed ID: 31009123
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A Comprehensive Computational Analysis for the Binding Modes of Hepatitis C Virus NS5A Inhibitors: The Question of Symmetry.
    Ahmed M; Pal A; Houghton M; Barakat K
    ACS Infect Dis; 2016 Nov; 2(11):872-881. PubMed ID: 27933783
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparison of daclatasvir resistance barriers on NS5A from hepatitis C virus genotypes 1 to 6: implications for cross-genotype activity.
    Wang C; Jia L; O'Boyle DR; Sun JH; Rigat K; Valera L; Nower P; Huang X; Kienzle B; Roberts S; Gao M; Fridell RA
    Antimicrob Agents Chemother; 2014 Sep; 58(9):5155-63. PubMed ID: 24936600
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Preclinical characterization of BMS-791325, an allosteric inhibitor of hepatitis C Virus NS5B polymerase.
    Lemm JA; Liu M; Gentles RG; Ding M; Voss S; Pelosi LA; Wang YK; Rigat KL; Mosure KW; Bender JA; Knipe JO; Colonno R; Meanwell NA; Kadow JF; Santone KS; Roberts SB; Gao M
    Antimicrob Agents Chemother; 2014 Jun; 58(6):3485-95. PubMed ID: 24733465
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Discovery of a Silicon-Containing Pan-Genotype Hepatitis C Virus NS5A Inhibitor.
    Liu B; Gai K; Qin H; Wang J; Liu X; Cao Y; Lu Q; Lu D; Chen D; Shen H; Song W; Mei J; Wang X; Xu H; Zhang Y
    J Med Chem; 2020 May; 63(10):5312-5323. PubMed ID: 32293179
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Discovery and Characterization of Potent Pan-Genotypic HCV NS5A Inhibitors Containing Novel Tricyclic Central Core Leading to Clinical Candidate.
    Ramdas V; Talwar R; Banerjee M; Joshi AA; Das AK; Walke DS; Borhade P; Dhayagude U; Loriya R; Gote G; Bommakanti A; Sivaram A; Agarwal G; Goswami A; Nigade P; Mehta M; Patil V; Modi D; Kumar H; Mallurwar S; Dash A; Modi F; Kuldharan S; Srivastava P; Singh M; Narasimham L; Gundu J; Sharma S; Kamboj RK; Palle VP
    J Med Chem; 2019 Dec; 62(23):10563-10582. PubMed ID: 31710479
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Studies of the symmetric binding mode of daclatasvir and analogs using a new homology model of HCV NS5A GT-4a.
    Saad KA; Eldawy MA; Elokely KM
    J Mol Model; 2022 Dec; 29(1):25. PubMed ID: 36580076
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Hepatitis C virus NS5A replication complex inhibitors: the discovery of daclatasvir.
    Belema M; Nguyen VN; Bachand C; Deon DH; Goodrich JT; James CA; Lavoie R; Lopez OD; Martel A; Romine JL; Ruediger EH; Snyder LB; St Laurent DR; Yang F; Zhu J; Wong HS; Langley DR; Adams SP; Cantor GH; Chimalakonda A; Fura A; Johnson BM; Knipe JO; Parker DD; Santone KS; Fridell RA; Lemm JA; O'Boyle DR; Colonno RJ; Gao M; Meanwell NA; Hamann LG
    J Med Chem; 2014 Mar; 57(5):2013-32. PubMed ID: 24521299
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.